Hoffman Robert E. 4

What Happened
Robert E. Hoffman, a director of TuHURA Biosciences (HURA), was granted 156,240 derivative securities (stock options) on February 12, 2026. The reported acquisition price is $0.00, which reflects an awarded option grant rather than a cash purchase or sale. This is an equity compensation award and not an immediate purchase or disposition of common stock.

Key Details

• Transaction date: February 12, 2026 (Form 4 filed February 17, 2026). Filing appears timely under Form 4 rules.
• Transaction type/code: Award/Grant (A); derivative securities (options) reported at $0.00.
• Quantity: 156,240 stock options granted.
• Shares owned after transaction: Not specified in the filing.
• Vesting/footnotes: Footnote F1 states this is an annual option grant under the 2024 Equity Incentive Plan with one-third of the options vesting on each of the first, second and third anniversaries of February 12, 2026. Footnote F2 references a prior annual option grant (Jan 2, 2025) with a similar one-third-per-year vesting schedule.
• No indication of a cashless exercise, sale, or tax-withholding reported in this filing.

Context
This transaction is a standard compensation grant to a director. Because these are options, they must vest (per the schedule above) before they can be exercised into shares; the grant itself does not represent immediate share ownership or a sale. Awards like this are common and don’t by themselves signal buying or selling sentiment.